RxDoctor Payments Data

Daniel Johnsrud, MD

Interventional Cardiology · Milwaukee, WINPI 1427437599

Payments from drug & device makers

What this record shows

This record is dominated by grants: $15,000 of the $24,703 with a category attached, or 60.7%. Medtronic accounts for 73.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $20,043 and has fallen 97.1% since, to $585 in 2025.

$24,703in general payments, 2019–2025

Across 102 payments — averaging $242.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$18K
  • Edwards Lifesciences$3K
  • Boston Scientific$1K
  • Abbott$683
  • Asahi Intecc USA, Inc.$323
  • Abiomed$300
  • plus $1K from 12 others
$15,559in research payments, 2019–2025

Across 16 payments — averaging $972.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$16K

What the payments were for

  • Grants$15,00061%
  • Travel & lodging$2,64411%
  • Food & beverage$6,90928%
  • Education$1491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,703 in reported general payments places this provider in the 80th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$86,850
Medicare patients
430
Services billed
2,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$146,900
EntrestoSacubitril/Valsartan102$112,458
JardianceEmpagliflozin78$60,850
XareltoRivaroxaban48$42,894
BrilintaTicagrelor30$22,640
Repatha SureclickEvolocumab22$16,730
Metoprolol Succinate313$4,916
Atorvastatin Calcium292$2,770
Carvedilol275$2,182
Ranolazine ErRanolazine18$2,001
Hydralazine Hcl68$1,666
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$1,529
ClopidogrelClopidogrel Bisulfate114$1,442
Bumetanide23$1,253
Furosemide243$1,231

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →